QT interval is prolonged but QT dispersion is maintained in patients with primary aldosteronism

International Journal of Clinical Practice

Volumn 61, Issue 3, 2007, Pages 392-396

  Yang, T Y ^a   Cheng, N J ^a   Ko, Yu Shien ^a,b   Kuo, C T ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; POTASSIUM; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEART REPOLARIZATION; HUMAN; HYPOKALEMIA; MALE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION;

ADULT; ALDOSTERONE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERALDOSTERONISM; LONG QT SYNDROME; MALE; MIDDLE AGED; POTASSIUM; REGRESSION ANALYSIS; RENIN; RETROSPECTIVE STUDIES;

EID: 33847049847     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00982.x     Document Type: Article

References (32)

1. Keren A, Tzivoni D, Gavish D et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation 1981; 64: 1167-74.
2. Mirvis DL, Goldberger AL. Electrocardiography. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease, 6th edn. Philadelphia: WB Saunders, 2001; pp. 82-128.
3. Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63: 342-4.
4. Priori SG, Napolitano C, Diehl L et al. Dispersion of repolarization as a marker to predict efficacy of anti-adrenergic therapy. Circulation 1994; 89: 1681-9.
5. Fu Z, Timonthy K, Fox J et al. Beta-blockers markedly affect QT dispersions during exercise in long QT syndrome patients. J Am Coll Cardiol 1993; 21: 93A (abstract).
6. Dristas A, Gilligan D, Nihoyannopoulos P et al. Amiodarone reduces QTc dispersion in patients with hypertrophic cardiomyopathy. Int J Cardiol 1992; 36: 345-9.
7. Granguly A. Primary aldosteronism. New Engl J Med 1998; 339: 1828-34.
8. Curry P, Fitchett D, Stubbs W et al. Ventricular arrhythmias and hypokalemia. Lancet 1976; 2: 231-3.
9. Krikler D, Curry P. Torsade de pointes, an atypical ventricular tachycardia. Br Heart J 1976; 38: 117-20.
10. Sade E, Oto A, Oner Z et al. Adrenal adenoma presenting with torsade de pointes - a case report. Angiology 2002; 53: 471-4.
11. Cheng H-W, Yang T-Y, Chung C-M. Torsade de pointes: a rare presentation of Conn's syndrome. Acta Cardiol Sin 2003; 19: 267-70.
12. Choy AM, Lang CC, Chomsky DM et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997; 96: 2149-54.
13. Lepeschekin E, Surawicz B. The measurement of the QT interval of the electrocardiogram. Circulation 1952; 6: 378-438.
14. Statters DJ, Malik M, Ward DD et al. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994; 8: 672-85.
15. Bazett HC. An analysis of the time-relations of electrocardiogram. Heart 1920; 7: 353-70.
16. Matsumura K, Fujii K, Kansui Y et al. Prolongation of the QT interval in primary aldosteronism. Clin Exp Pharmacol Physiol 2005; 32: 66-9.
17. Surawicz B, Braun HA, Crum WB et al. Quantitative analysis of the electrocardiographic pattern of hypopotassemia. Circulation 1957; 16: 750-82.
18. Tillmann HC, Schumacher B, Yasenyev O et al. Acute effects of aldosterone on intracardiac monophasic action potentials. Int J Cardiol 2002; 84: 33-9.
19. De Mello WC. Aldosterone modulates the effect of angiotensin II on the electrical properties of rat heart. J Cardiovasc Pharmacol 2002; 40: 90-5.
20. Hii JTY, Wyse DG, Gillis AM et al. Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drug and amiodarone. Circulation 1992; 86: 1376- 82.
21. Sylvein JC, Horacek BM, Spencer CA et al. QT interval variability on the body surface. J Electrocardiol 1984; 17: 179-88.
22. Cowan JC, Yusoff K, Moore M et al. Importance of lead selection in QT interval measurement. Am J Cardiol 1988; 61: 83-7.
23. Yelamanchi VP, Molnar J, Ranade V et al. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography. Am J Ther 2001; 8: 117-22.
24. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001; 37: 1800-7.
25. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
26. Akbulut M, Ozbay Y, Ilkay E et al. Effects of spironolactone and metoprolol on QT dispersion in heart failure. Jpn Heart J 2003; 44: 681-92.
27. Caballero R, Moreno I, Gonzalez T et al. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-gorelated gene channels. Circulation 2003; 107: 889-95.
28. White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 2003; 88: 2376-83.
29. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? J Electrocardiol 2004; 37 (Suppl.): 15-24.
30. Sheehan J, Perry IJ, Reilly M et al. QT dispersion, QT maximum and risk of cardiac death in the Caerphilly Heart Study. Eur J Cardiovasc Prev Rehabil 2004; 11: 63-8.
31. Algra A, Tijssen JG, Roelandt JR et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83: 1888-94.
32. Schouten EG, Dekker JM, Meppelink P et al. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991; 84: 1516-23.